Welcome to our dedicated page for Vistagen Therapeutics news (Ticker: VTGN), a resource for investors and traders seeking the latest updates and insights on Vistagen Therapeutics stock.
Vistagen Therapeutics, Inc. develops late clinical-stage biopharmaceutical programs based on nose-to-brain neurocircuitry and intranasal pherine product candidates. Company news centers on fasedienol nasal spray for the acute treatment of social anxiety disorder, including PALISADE Phase 3 study updates, and refisolone nasal spray for vasomotor symptoms due to menopause.
Recurring updates also cover FDA and IND communications, clinical data from psychiatric and neurological programs, fiscal results, cash-management actions, executive and board changes, and healthcare investor conference presentations. The company’s pipeline is described around investigational intranasal candidates for indications that include social anxiety disorder, major depressive disorder, and menopausal hot flashes.
Vistagen (Nasdaq: VTGN) will present a corporate overview at the 46th Annual TD Cowen Healthcare Conference on Monday, March 2, 2026 at 3:50 p.m. ET. President and CEO Shawn Singh will deliver the presentation. A replay will be archived on the company’s Investors > Events page at Vistagen.com.
Vistagen (NASDAQ: VTGN) reported fiscal Q3 2026 results and a corporate update emphasizing its PALISADE Program and pipeline progress. The company expects topline randomized results from the PALISADE-4 Phase 3 trial of fasedienol in the first half of 2026. Cash, cash equivalents, and marketable securities totaled $61.8 million as of December 31, 2025.
PALISADE-3 did not meet its primary endpoint, though randomized safety data were favorable. Vistagen named a new CFO and plans an IND submission for refisolone in H1 2026 while continuing cash-preservation measures.
Vistagen (Nasdaq: VTGN) will report fiscal year 2026 third quarter results and hold a corporate update conference call on February 12, 2026 at 2:00 p.m. PT / 5:00 p.m. ET. The event will be webcast live and archived for at least 90 days.
Investors can register for the webcast or pre-register for dial-in access; registrants will receive access details by email.
Vistagen (NASDAQ: VTGN) announced topline results from the PALISADE-3 Phase 3 public speaking challenge study of intranasal fasedienol for acute social anxiety disorder.
The study did not meet its primary endpoint: least squares mean change in SUDS was 13.6 (±1.54 SE) for fasedienol vs 14.0 (±1.51 SE) for placebo, a LS mean difference of 0.4 (p = not significant). There were no treatment differences on secondary endpoints. Safety and tolerability were reported as favorable and consistent with prior trials. Management said it will review results with the FDA, evaluate program impact, and has implemented company-wide cash preservation measures intended to provide runway into 2027.
Vistagen (Nasdaq: VTGN) appointed Nick Tressler as Chief Financial Officer effective December 1, 2025. Mr. Tressler has over 20 years of life‑science financial leadership, most recently serving as CFO of DYNEX Technologies and previously at American Gene Technologies and Senseonics (Nasdaq: SENS). He held senior roles at Sucampo (acquired 2018) and MedImmune (acquired 2007) and holds an MBA from Johns Hopkins.
The Compensation Committee granted an inducement incentive option for 150,000 shares with an exercise price equal to the December 1, 2025 closing price; vesting is 25% after one year, then monthly ratable vesting over 36 months.
Vistagen (Nasdaq: VTGN) presented exploratory data at The Menopause Society 2025 Annual Meeting showing that intranasal PH80 produced rapid-onset effects on autonomic biomarkers of vasomotor symptoms without systemic absorption. The company reported PH80 was not detected in human blood, did not bind steroid hormone or neurotransmitter receptors, and dose-dependently depolarized nasal receptor electrograms (EGNR).
These studies, conducted 1995–2000 and sponsored by Pherin Pharmaceuticals (now a Vistagen subsidiary), support a proposed non-hormonal, non-systemic, rapidly acting mechanism for treating menopausal hot flashes; posters are available on the company publications page.
Vistagen (Nasdaq: VTGN) reported fiscal 2026 second quarter results and a program update on November 13, 2025. PALISADE-3 randomized, double-blinded portion is complete and topline results are expected in Q4 2025. A duplicate trial, PALISADE-4, has topline randomized results expected in the first half of 2026. For the three months ended September 30, 2025, R&D expense was $15.9 million (prior-year $10.2M), G&A expense $4.4 million (prior-year $4.2M), and net loss was $19.4 million (prior-year $13.0M). Cash, cash equivalents, and marketable securities were $77.2 million as of September 30, 2025. The company also announced a board appointment and is hosting a conference call on November 13, 2025 at 5:00 p.m. ET.
Vistagen (Nasdaq: VTGN) will report fiscal year 2026 second quarter results for the period ended September 30, 2025 and host a corporate update conference call on Thursday, November 13, 2025 at 2:00 p.m. PT / 5:00 p.m. ET. The event will be webcast live via the Investors > Events section of the company website; registration is recommended at least 10 minutes before the call. The webcast will be archived on the company website and available for at least 90 days. Dial-in details: Conference ID 6458570, Toll-Free 1(646) 307-1952, International 1(646) 307-1963.
Vistagen (Nasdaq: VTGN) announced that President and CEO Shawn Singh will participate in a fireside chat at the Stifel Healthcare Conference on Wednesday, November 12, 2025 from 3:20–3:50 p.m. ET.
The company will host one-on-one meetings during the conference and a live webcast will be available via the Events page in the Investors section at www.Vistagen.com. A replay of the webcast will be archived and available after the event.
Vistagen (Nasdaq: VTGN) announced completion of the randomized, double-blind, placebo-controlled portion of the PALISADE-3 Phase 3 public speaking challenge study for the acute treatment of social anxiety disorder. The company said topline results are expected by year-end 2025 and an open-label extension is ongoing where participants may use fasedienol for up to 12 months.
Vistagen noted PALISADE-3 uses the same design and primary endpoint as the previously positive PALISADE-2 trial, and that PALISADE-4 topline results are anticipated in first half of 2026. The FDA has granted Fast Track designation for fasedienol for acute social anxiety disorder.